Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial
- 26 November 2012
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 58 (4), 663-668
- https://doi.org/10.1016/j.jhep.2012.11.018
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences, Inc.
This publication has 7 references indexed in Scilit:
- Pharmacokinetics, Pharmacodynamics, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor, following Multiple Ascending Doses in Patients with Chronic Hepatitis C InfectionAntimicrobial Agents and Chemotherapy, 2013
- New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectivesGut, 2012
- Chronic hepatitis C: Treatments of the futureClinics and Research in Hepatology and Gastroenterology, 2011
- Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C VirusJournal of Medicinal Chemistry, 2010
- The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2008
- Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replicationBioorganic & Medicinal Chemistry Letters, 2006
- Structure−Activity Relationship of Heterobase-Modified 2‘-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA ReplicationJournal of Medicinal Chemistry, 2004